Company webinar

Avecho Biotechnology (ASX:AVE)

Watch our webinar with Avecho Biotechnology, featuring CEO Dr Paul Gavin. A presentation followed by live Q&A with the audience.

Date
March 26, 2025
Time
Where
Online
Entry
Free
Dr Paul Gavin
Dr Paul Gavin
CEO, Avecho Biotechnology (ASX:AVE)

About the company

Avecho Biotechnology Limited develops innovative pharmaceutial products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs to create medicines with better therapeutic effect. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) capsule currently undergoing Phase III clinical development for the treatment of insomnia.

Key topics

  • Description of Avecho’s proprietary CBD capsule currently and Phase III trial
  • Unmet need and commercial opportunity for the product
  • Recent landmark licensing deal with Sandoz for commercial rights to the product in Australia
  • Upcoming key inflection points/milestones

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →